drugset / Trial / NCT02684084

Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema

NCT02684084

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a 24-week, prospective, multi-center, open-label, randomized, investigator-initiated pilot study to explore the effects of RBZ (0.5 mg) plus DEX implant (0.7 mg) PRN combination therapy (n = 30) vs. DEX implant PRN monotherapy (n = 30) in pseudophakic eyes with center-involved DME that have demonstrated prior incomplete response to 3-6 anti-VEGF treatments.

Timeline

Start
2015-11
Primary completion
2016-11
Completion
2016-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexamethasone Small molecule 0.7 mg
Comparator Ranibizumab Monoclonal antibody 0.5 mg Intravitreal